Skip to main content

Nasdaq IPOs

Phase 3 biotech Angion Biomedica files for a $75 million IPO

5 years 8 months ago
Angion Biomedica, a Phase 3 biotech developing small molecule therapies for acute organ injuries, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company had previously filed to raise $30 million in May 2014 but withdrew the following Oc
Renaissance Capital

Cancer biotech Immunocore files for a $100 million US IPO

5 years 8 months ago
Immunocore Holdings, Phase 3 biotech developing T Cell therapies for cancer and other diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Abingdon, United Kingdom-based company was founded in 2007 and booked $39 million in milest
Renaissance Capital

Cell therapy biotech Vor Biopharma files for a $150 million IPO

5 years 8 months ago
Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering. The company's pipeline contains its lead engineered hematopoietic stem cell (eHSC) candidate, VOR
Renaissance Capital

Dutch rare disease biotech Pharvaris files for a $100 million US IPO

5 years 8 months ago
Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is focused on the development of innovative therapies for rare diseases with significant
Renaissance Capital

NASH biotech Terns Pharmaceuticals files for a $100 million IPO

5 years 8 months ago
Terns Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for NASH, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's most advanced program is TERN-101, a liver-distributed, non-bile acid
Renaissance Capital

Cancer biotech Sensei Biotherapeutics files for a $100 million IPO

5 years 8 months ago
Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Sensei's proprietary ImmunoPhage platform is designed to utilize bacteriophage to induce an inna
Renaissance Capital
Checked
8 minutes 18 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed